摘要 |
hES cells and/or their derivatives are used for treatment of skin disorders, said treatment comprising administering 750,000 to 160 million hES cells and/or their derivatives, wherein said cells comprise hematopoietic stem cell progenitors, via subcutaneous or intravenous injection. |